

Casgevy (exagamglogene-autotemcel) for Transfusion-Dependent B- Thalassemia Criteria

Revised: 07/01/2025

CASGEVY (EXAGAMGLOGENE-AUTOTEMCEL) FOR TRANSFUSION-DEPENDENT B-THALASSEMIA

Length of Authorization: One treatment course (12 months)

CRITERIA TO APPROVE

Transfusion-Dependent β -Thalassemia

- Age 12 years or older with transfusion-dependent β -thalassemia
 - Transfusion dependence is defined as a minimum of at least 100 mL/kg/year or 10 units/year of RBC transfusions in the most recent two years.
- Prescriber is a specialist at a qualified treatment center for Casgevy
- Patient does not have a contraindication to the prescribed medication
- Patient has not previously received gene therapy for the requested diagnosis.
- Patient has not previously received an allogeneic or autologous HSCT

RENEWAL CRITERIA

Not applicable as no further authorizations will be provided

REVISION HISTORY

07/01/2025	• Criteria Created
------------	--------------------